Adding the clinical framing, because it changes how the question reads.
My insurance denied my PA related to cost and coverage. Has anyone successfully appealed? I'm considering going compounded instead.
Dr.AddMedPHL said:My insurance denied my PA related to cost and coverage.
Second this.
Dr.AddMedPHL said:My insurance denied my PA related to cost and coverage.
Dr.AddMedPHL said:...my insurance denied cost and coverage coverage because...
Insurance denial is the single biggest barrier to GLP-1 access. Let me share the appeal framework that worked for me and several community members:
- Document medical necessity (BMI, comorbidities, failed alternatives)
- Reference clinical practice guidelines (AGA, AACE, Endocrine Society)
- Cite cost-effectiveness data (preventing diabetes/surgery saves money long-term)
- Request peer-to-peer review between your doctor and the plan's medical director
- File external appeal with your state insurance department if internal appeal fails
Don't accept the first denial. The appeal process exists for a reason.
Sigma-Aldrich — Research-Grade Standards
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsAdding the numbers, since they settle part of this. Worth knowing that the injection site changes very little. Abdomen, thigh and upper arm are bioequivalent for semaglutide, so a site change is not a plausible explanation for a bad week.
Following on from Dr.AddMedPHL — and this may be the naive question:
Whether anyone has held at a sub-maximal dose long term and kept the result, or whether the maintenance data only exists at 2.4mg?